Cure8 research brief
Why This Matters
Genetic factors play a key role in some IBD cases and could help match patients to targeted treatments. Current genetic tests can miss important causes, so broader or different testing approaches may be needed to find treatable genetic contributors.
Who Should Pay Attention
Clinicians caring for IBD patients (adult and pediatric), geneticists and immunologists, researchers in IBD genetics and microbiome, and patients or families with early-onset, atypical, or treatment-refractory IBD.
Study Snapshot
What To Know
This article abstract reviews the genetic architecture of IBD (monogenic, oligogenic, polygenic), discusses limitations of standard genetic screening (including mosaicism and regulatory variants), and argues for immunogenetic pathway–based classification to guide precision therapeutics.
The summary below is grounded in the source-provided abstract (structured content depth: abstract).
Keep In Mind
This classification is based on the article abstract; it is not a full-text review. The authors emphasize that negative genetic screens do not rule out genetic causes because newer mechanisms (mosaicism, regulatory variants) may be undetected by routine tests. Implementing pathway-based genetic evaluation may require specialized testing and interpretation.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.